1. |
Zhdanava M, Pesa J, Boonmak P, et al. Predictors of high healthcare cost among patients with generalized myasthenia gravis: A combined machine learning and regression approach from a US payer perspective. Appl Health Econ Health Policy, 2024, 22(5): 735-747.
|
2. |
马骏, 林洁桓, 陈福楠, 等. 小剂量他克莫司在胸腺瘤合并全身型重症肌无力术后的应用. 北方药学, 2022, 19(7): 189-192.Ma J, Lin JH, Chen FN, et al. Application of low-dose tacrolimus in the postoperative management of thymoma with generalized myasthenia gravis. North Pharm, 2022, 19(7): 189-192.
|
3. |
广东省药学会. 围手术期糖皮质激素医-药专家共识. 今日药学, 2021, 31(10): 721-731.Expert consensus on the perioperative glucocorticoids management. Pharm Today, 2021, 31(10): 721-731.
|
4. |
中华医学会神经病学分会神经免疫学组, 中国免疫学会神经免疫学分会. 中国重症肌无力诊断和治疗指南2015. 中华神经科杂志, 2015, 48(11): 934-940.The Chinese Medical Association Neurology Branch Immunology Group, Chinese Medical Association Neurology Branch Immunology Group. Chinese guidelines for diagnosis and treatment of myasthenia gravis 2015. Chin J Neurol, 2015, 48(11): 934-940.
|
5. |
Alhaidar MK, Abumurad S, Soliven B, et al. Current treatment of myasthenia gravis. J Clin Med, 2022, 11(6): 1597.
|
6. |
常婷. 中国重症肌无力诊断和治疗指南(2020版). 中国神经免疫学和神经病学杂志, 2021, 28(1): 1-12.Change T. Chinese guidelines for diagnosis and treatment of myasthenia gravis (2020 edition). Chin J Neuroimmunol Neurol, 2021, 28(1): 1-12.
|
7. |
糖皮质激素急诊应用共识专家组. 糖皮质激素急诊应用专家共识. 中华急诊医学杂志, 2020, 29(6): 765-772.Committee of Expert Consensus on Emergency Application of Glucocorticoids. Expert consensus on emergency application of glucocorticoids. Chin J Emer Med, 2020, 29(6): 765-772.
|
8. |
Horiuchi K, Nakamura S, Yamada K, et al. Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: A case series. Neuromuscul Disord, 2024, 39: 37-41.
|
9. |
Prerna M, Trapty A, Daxa V, et al. OntoMG: A unique and ontological-based intelligent framework for early identification of myasthenia gravis (MG). Int J Inf Technol, 2014, 16(6): 3847-3853.
|
10. |
Wiłkość-Dębczyńska M, Liberacka-Dwojak M, Rzepiński Ł, et al. Diurnal cognitive functioning in patients with myasthenia gravis with the role of chronotype and depression: A pilot study. Postep Psychiatr Neurol, 2024, 33(2): 49-53.
|
11. |
陈渊, 张鹏. 重症肌无力外科治疗京津冀专家共识. 天津医药, 2020, 48(04): 327-332.Chen Y, Zhang P. Consensus on surgical treatment of myasthenia gravis of the Jing-Jin-Ji experts. Tianjin Med J, 2020, 48(04): 327-332.
|
12. |
Frisaldi E, Ferrero B, Di Liberto A, et al. The impact of patients' pre-treatment expectations on immunosuppressive treatment outcomes in myasthenia gravis: A pilot correlational study. Muscle Nerve, 2024, 70(3): 413-419.
|
13. |
Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology, 2016, 87(4): 419-425.
|
14. |
欧昶毅, 冉昊, 邱力, 等. 127例次重症肌无力患者危象前状态相关因素的分析. 中华医学杂志, 2017, 97(37): 2884-2889.Ou CY, Ran H, Qiu L, et al. Correlation factors of 127 times pre-crisis state in patients with myasthenia gravis. Natl Med J China, 2017, 97(37): 2884-2889.
|
15. |
Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: Current questions and tentative answers in rheumatology. Ann Rheum Dis, 2002, 61(8): 718-722.
|